Introduction Non-Hodgkin lymphoma (NHL) is a lymphoid malignancy that represents 4.3% of all new cancer diagnosis in the United States and is estimated to be responsible for over 19,000 deaths in 2020. While newer immunotherapies have emerged that have improved…
Introduction Light chain (AL) amyloidosis is a plasma cell disorder characterized by the deposition of monoclonal immunoglobulin light chains in a variety of tissues leading to organ dysfunction. The treatment of this disorder focuses on eliminating the plasma cells producing…
Introduction Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow microenvironment causing organ dysfunction that may include anemia, lytic bone lesions, hypercalcemia, and renal dysfunction. In 2021, myeloma was expected…
Introduction The goal of treatment for multiple myeloma, an incurable hematologic malignancy, is to achieve the deepest possible response with the longest duration of remission upfront to achieve a durable disease-free state. The pivotal multicenter trial IFM 90 established the…
CASE STUDY A 19-year-old Caucasian male presented with petechiae and a platelet count of 4 × 10 9 /L, neutrophils 0.3 × 10 9 /L, hemoglobin 9 g/dL with reticulocyte count of 0.019 × 10 9 Bone marrow aspirate…
Introduction Myeloproliferative neoplasms (MPN) are a heterogeneous group of myeloid stem cell disorders shared by certain clinical and biological similarities, and characterized by clonal myeloproliferation without significant dyserythropoiesis, granulocytic dysplasia, or monocytosis. Primary myelofibrosis (PMF), polycythemia vera (PV), and essential…
Key Concepts Hematopoietic cell transplantation provides a curative therapy for patients with myelodysplastic syndrome. The clonal karyotype is the strongest predictor of posttransplant relapse. The availability of human leukocyte antigen (HLA)-matched related and unrelated donors, HLA-haploidentical donors, and umbilical cord…
Disclosures: FTA has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme. PRG has provided consultancy to: Pharmacyclics…
Introduction Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies with an annual age-adjusted incidence rate of 1.8 per 100,000 people in the United States, with an estimated 5690 new cases and 1580 deaths according to the most…
Introduction Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies with an annual age-adjusted incidence rate of 1.73 per 100,000 people in the United States and with a median age of 14 years. It is estimated that 5690…